Advisornet Financial’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.42K Buy
18
+14
+350% +$4.22K ﹤0.01% 1745
2026
Q1
$1.32K Sell
4
-2
-33% -$681 ﹤0.01% 1973
2025
Q4
$2.39K Sell
6
-15
-71% -$6.64K ﹤0.01% 1880
2025
Q3
$9.58K Buy
21
+18
+600% +$7.33K ﹤0.01% 1533
2025
Q2
$978 Hold
3
– – ﹤0.01% 1946
2025
Q1
$810 Hold
3
– – ﹤0.01% 1909
2024
Q4
$706 Sell
3
-8
-73% -$2.1K ﹤0.01% 1719
2024
Q3
$3.02K Buy
11
+1
+10% +$260 ﹤0.01% 1683
2024
Q2
$2.43K Sell
10
-13
-57% -$2.05K ﹤0.01% 1594
2024
Q1
$3.44K Buy
23
+15
+188% +$2.5K ﹤0.01% 1510
2023
Q4
$1.53K Sell
8
-1
-11% -$170 ﹤0.01% 1786
2023
Q3
$1.59K Sell
9
-15
-63% -$2.86K ﹤0.01% 1698
2023
Q2
$4.56K Sell
24
-10
-29% -$1.98K ﹤0.01% 1528
2023
Q1
$6.81K Buy
34
+27
+386% +$5.67K ﹤0.01% 1403
2022
Q4
$1.66K Buy
7
+5
+250% +$1.07K ﹤0.01% 1711
2022
Q3
$0 Buy
+2
New +$381 ﹤0.01% 1855

Other funds holding ALNY

Advisornet Financial's ALNY Position: Q2 2026 in Review

Advisornet Financial increased its Alnylam Pharmaceuticals (ALNY) stake by 350% in Q2 2026, buying an estimated $4.22K and bringing the position to 18 shares worth $5.42K. The position accounts for ﹤0.01% of the portfolio, ranked #1745.

Advisornet Financial first reported a position in ALNY in Q3 2022 and has held it in 16 quarters since. The position peaked at $9.58K in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Advisornet Financial held 18 shares of Alnylam Pharmaceuticals worth $5.42K as of Q2 2026.
  • Advisornet Financial bought 14 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $4.22K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Advisornet Financial's portfolio in Q2 2026, its #1745 holding.
  • Advisornet Financial first reported a position in Alnylam Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • Advisornet Financial's Alnylam Pharmaceuticals position peaked at $9.58K in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Advisornet Financial's 13F filing for Q2 2026, filed 23 Jul 2026.